Markou Athina, Tsaroucha Emily G, Kaklamanis Loukas, Fotinou Marianthi, Georgoulias Vassilis, Lianidou Evi S
Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece.
Clin Chem. 2008 Oct;54(10):1696-704. doi: 10.1373/clinchem.2007.101741. Epub 2008 Aug 21.
microRNA (miRNA) expression profiles are being intensively investigated for their involvement in carcinogenesis. We evaluated the prognostic value of mature microRNA-21 (miR-21) and mature microRNA-205 (miR-205) overexpression in non-small cell lung cancer (NSCLC).
We studied 48 pairs of NSCLC fresh frozen tissue specimens collected at time of surgery and before chemotherapy. Highly specific amplification and quantification of mature miR-21 and mature miR-205 was achieved using looped real time RT-PCR.
miRNA expression, determined by real time RT-PCR, was defined by DeltaDeltaCt measurements. We detected overexpression of mature miR-21 in 25 (52.0%) of the 48 NSCLC paired specimens and overexpression of miR-205 in 31 (64.6%). Overexpression was assessed after comparison of miRNA expression in NSCLC tissues and in their corresponding noncancerous tissues with respect to U6 expression. During the follow-up period, 29 of 48 (60.4%) patients relapsed, and 23 of 48 died (47.9%). Mature miR-21 was upregulated in 16 of 29 (55.2%) patients who relapsed and 15 of 23 (65.2%) patients who died. Mature miR-205 was overexpressed in 19 of 29 patients who relapsed (65.5%) and 15 of 23 patients who died (65.2%). Mature miR-21 overexpression correlated with overall survival (OS) of the patients (P = 0.027), whereas overexpression of mature miR-205 did not.
Our results suggest that overexpression of mature miR-21 is an independent negative prognostic factor for OS in NSCLC patients.
微小RNA（miRNA）表达谱因其在致癌过程中的作用而受到深入研究。我们评估了成熟微小RNA-21（miR-21）和成熟微小RNA-205（miR-205）过表达在非小细胞肺癌（NSCLC）中的预后价值。
我们研究了48对在手术时和化疗前收集的NSCLC新鲜冷冻组织标本。使用环化实时逆转录聚合酶链反应实现了成熟miR-21和成熟miR-205的高特异性扩增和定量。
通过实时逆转录聚合酶链反应测定的miRNA表达由ΔΔCt测量值定义。我们在48对NSCLC配对标本中的25对（52.0%）中检测到成熟miR-21过表达，在31对（64.6%）中检测到miR-205过表达。在将NSCLC组织及其相应的非癌组织中的miRNA表达相对于U6表达进行比较后评估过表达情况。在随访期间，48例患者中有29例（60.4%）复发，48例中有23例死亡（47.9%）。成熟miR-21在29例复发患者中的16例（55.2%）和23例死亡患者中的15例（65.2%）中上调。成熟miR-205在29例复发患者中的19例（65.5%）和23例死亡患者中的15例（65.2%）中过表达。成熟miR-21过表达与患者的总生存期（OS）相关（P = 0.027），而成熟miR-205过表达则不然。
我们的结果表明，成熟miR-21过表达是NSCLC患者OS的独立负性预后因素。
